Robert Fox, MD

Robert Fox, MD, is a Staff Neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic. He received his medical degree from Johns Hopkins University, neurology residency training at the University of Pennsylvania, multiple sclerosis fellowship training at Cleveland Clinic, and a master’s degree in Clinical Research from Case Western Reserve University.

He serves as an advisory committee member and principal site investigator for many clinical trials, including coordinating global principal investigator for a Phase III clinical trial of dimethyl fumarate in relapsing remitting multiple sclerosis (MS).

Dr. Fox’s current research interests focus on innovative MRI techniques to evaluate MS treatments and tissue recovery after injury, where he is principal investigator and co-investigator on grants funded by the NIH and National MS Society. He serves as a member of various advisory and review committees for the National MS Society. He is also Managing Director of the NARCOMS MS Patient Registry, a member of the General Advisory Council and Research Programs Committee for the Cleveland Clinic General Clinical Research Center, and a consultant to the pharmaceutical industry regarding the development of new treatments for MS.

Education & Professional Highlights

Appointed
2002

Education & Fellowships

Graduate School - Case Western Reserve University School of Medicine
Cleveland, OH USA
2003

Fellowship - Cleveland Clinic
Neuroimmunology
Cleveland, OH USA
2002

Residency - Hospital of The University of Pennsylvania
Neurology
Philadelphia, PA USA
2000

Internship - Hospital of The University of Pennsylvania
Medicine
Philadelphia, PA USA
1997

Medical Education - Johns Hopkins University School of Medicine
Baltimore, MD USA
1996

Undergraduate - Amherst College
Amherst, MA USA
1991

Additional Training

Masters of Science in Clinical Research, Case Western Reserve University, 2003

Professional Highlights

Advisory Committee on Fellowships, National Multiple Sclerosis Society (Chair, 2011-2012)
International Coordinating Investigator, Phase III clinical trial of BG00012
Editorial Board, Neurology and Multiple Sclerosis Journal
Managing Director, NARCOMS MS Patient Registry
Scientific Expert Working Group on CCSVI, Canadian Institutes of Health Research
MS Clinical Phenotype Subcommittee, International Advisory Committee on Clinical Trials in MS
Medical Monitor, Phase I Study of Mesenchymal Stem Cell Transplantation in MS
Ad hoc reviewer, NIH ZRG1 BDCN-N Member Conflict Special Emphasis Panel
Committee for Responsible Research Conduct, Cleveland Clinic
Neurosciences Sub-Chair, Research Programs Committee, Cleveland Clinic

Specialty Interests

Multiple Sclerosis, Neuroimmunology

Awards & Honors

1991 James Olds Memorial Neuroscience Thesis Award
1992 Alpha Omega Alpha Honor Society Grant
1996 Sellards Travel Award to Johannesburg, South Africa
1996 Medical and Chirurgical Society of Maryland Award for Excellence in Organized Medicine
1996 Harold Lamport Biomedical Research Prize, Johns Hopkins University
1999 Zeritzky Resident Clinical Research Award, University of Pennsylvania
2000 Potiker Fellow, Mellen Center for Multiple Sclerosis Treatment and Research
2001 National Multiple Sclerosis Society Dale McFarlin Travel Award
2003-2012 Top Doctors, Cleveland Magazine
2008 Outstanding Physician/PA Team, Cleveland Clinic
2009 Fellow, American Academy of Neurology
2011 Researcher Hall of Fame, National MS Society

Memberships

American Academy of Neurology
American Society of Neuroimaging
American Medical Association

Research & Publications

See publications for Robert Fox, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 7/25/2022, Dr. Fox has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Fox receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

Novartis International, AG
Janssen Pharmaceuticals, Inc.
Celgene Corporation (a wholly-owned subsidiary of Bristol-Myers Squibb)
Sanofi Genzyme
Immunic, Inc.
Biogen Idec, Inc.
Greenwich Biosciences, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Primary Location

Cleveland Clinic Main Campus

Additional Locations

Treatment & Services

Specialty in Diseases & Conditions

Insurance

Is Cleveland Clinic Part of Your Insurance?